Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Indoramin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.98 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.98 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.98 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.98 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.98 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.98 |
| ▸ | BCHE known ✓ | P06276 | 3/20 | 0.61 |
| ▸ | ACHE known ✓ | P22303 | 3/20 | 0.61 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.59 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.58 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.58 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.56 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.53 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.53 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.53 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.53 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.52 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indoramin SCHEMBL29801648 | 1.00 | ADRA1D (0.98) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| Indoramin SCHEMBL49517 | 0.99 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| Indoramin SCHEMBL29370437 | 0.99 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| Indoramin SCHEMBL1651262 | 0.97 | ADRA1D (0.96) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL11545694 | 0.92 | ADRA2A (0.83) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| SCHEMBL11303310 | 0.91 | ADRA2A (0.85) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| SCHEMBL11506582 | 0.91 | ADRA2A (0.85) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| SCHEMBL11545710 | 0.90 | ADRA2A (0.83) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| SCHEMBL11070428 | 0.89 | ADRA2A (0.81) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| SCHEMBL10783732 | 0.88 | ADRA2A (0.80) | ADRA1DADRA1AADRA1BADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553091-A1 | HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-07-13 | — | — | EP | claimed |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | claimed |
| EP-0067539-B1 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION | JOHN WYETH & BROTHER LIMITED (GB) | 1985-09-18 | — | — | EP | claimed |
| US-4524060-A | PELLET MIXTURE OF INDORAMIN, CELLULOSE, AND WETTING AGENT IN GASTRIC JUICE PERMEABLE COATINGS | JOHN WYETH & BROTHER LIMITED (GB) | 1985-06-18 | — | — | US | claimed |
| EP-0067539-A2 | Sustained release pharmaceutical composition | JOHN WYETH & BROTHER LIMITED (GB) | 1982-12-22 | — | — | EP | claimed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| US-12296085-B2 | Method for extracorporeal treatment of preeclampsia and related disorders | ImMutriX Therapeutics, Inc. (US) | 2025-05-13 | — | — | US | disclosed |
| EP-3689357-B1 | COMPOSITIONS FOR CELLULAR RESTORATION AND METHODS OF MAKING AND USING SAME | ADVANCED REGEN MEDICAL TECH LLC (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024215303-A1 | NOVEL DRUG DELIVERY SYSTEMS AND METHODS OF MAKING AND USING SAME | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2024-10-17 | — | — | WO | disclosed |
| EP-4445915-A2 | CELL FREE COMPOSITIONS FOR CELLULAR RESTORATION AND METHODS OF MAKING AND USING SAME | Advanced Regen Medical Technologies, LLC (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| US-20240294909-A1 | AGENTS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF HYPOXIA AND ISCHEMIA-RELATED DISORDERS | MERAND PHARMACEUTICALS INC (US) | 2024-09-05 | — | — | US | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| US-5461140-A | Bioerodible polymers for solid controlled release pharmaceutical compositions | PHARMACEUTICAL DELIVERY SYSTEMS (US) | 1995-10-24 | — | — | US | disclosed |
| EP-0067539-B1 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION | JOHN WYETH & BROTHER LIMITED (GB) | 1985-09-18 | — | — | EP | disclosed |
| US-4524060-A | PELLET MIXTURE OF INDORAMIN, CELLULOSE, AND WETTING AGENT IN GASTRIC JUICE PERMEABLE COATINGS | JOHN WYETH & BROTHER LIMITED (GB) | 1985-06-18 | — | — | US | disclosed |
| EP-0067539-A2 | Sustained release pharmaceutical composition | JOHN WYETH & BROTHER LIMITED (GB) | 1982-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | ADRA1D 4164/4885ADRA1A 3821/4885ADRA1B 3771/4885 |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | CACNA1G, CACNA1F, CACNA1H | ADRA1D 593/4885ADRA1A 687/4885ADRA1B 417/4885 |
| US-12296085-B2 | Method for extracorporeal treatment of preeclampsia and related disorders | TEK, FLT4, PGF | ADRA1D 2711/4885ADRA1A 3697/4885ADRA1B 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.